RESUMEN
BACKGROUND/PURPOSE: Substantial progress was made in acute kidney injury (AKI) over the past 10 years, but no therapeutic interventions have been shown to prevent AKI or accelerate functional recovery after injury. A large number of preclinical studies supports the use of recombinant human erythropoietin (rHuEPO) to prevent AKI, but the clinical trial data are inconclusive. To address concerns about preclinical study design and reporting in AKI, we here presented our rigorous experiments on the use of rHuEPO in a mouse model simulating the most common post-ischemic AKI in patients. METHODS: Use of saline vehicle or rHuEPO (100 or 1000 U/KgBW) in mice subjected to AKI induced by ischemia-reperfusion injury of left kidney 2 weeks after right nephrectomy (NX + IRI). RESULTS: NX + IRI resulted in a reproducible AKI model. Use of rHuEPO as a pretreatment or posttreatment did not affect AKI severity, functional recovery, and mouse survival regardless of gender, injury severity, or doses of rHuEPO. Administering rHuEPO with 1000 U/KgBW did increase hematocrit and modulate AKI kidney macrophages by Nos2 downregulation and Ccl17 upregulation. Active expression of erythropoietin receptor (EPOR) was not identified in renal cells by lineage tracing study, whereas expression of colony-stimulating factor 2 receptor ß (CSF2Rß) was identified in kidney macrophages and upregulated after AKI. Both EPOR and CSF2Rß were identified in cultured bone marrow derived macrophages, possibly mediated the robust inhibition of cytokine-induced phenotype switching by rHuEPO. CONCLUSION: Use of rHuEPO can modulate macrophage function but not the post-ischemic AKI severity, functional recovery and survival in mice.
Asunto(s)
Lesión Renal Aguda/tratamiento farmacológico , Eritropoyetina/farmacología , Macrófagos/efectos de los fármacos , Daño por Reperfusión/fisiopatología , Transducción de Señal/efectos de los fármacos , Lesión Renal Aguda/etiología , Animales , Apoptosis/efectos de los fármacos , Modelos Animales de Enfermedad , Femenino , Riñón/efectos de los fármacos , Riñón/cirugía , Macrófagos/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Nefrectomía , Proteínas Recombinantes/farmacologíaRESUMEN
Simultaneous pancreas-kidney (SPK) transplantation is the primary surgical treatment for type I diabetes mellitus with end-stage renal disease. However, this transplant surgery has a high-risk of surgical complications, including duodenal anastomotic leakage, which may lead to pancreas transplantation failure if the leakage worsens. This case report describes a patient who suffered from duodenal anastomotic leakage after SPK transplantation. The digestive enzymes eroded the wound and skin around the wound, resulting in periwound moisture-associated dermatitis. During the period of nursing care, the wound-care intervention was determined by interdisciplinary cooperation. In our case report, the periwound moisture-associated dermatitis healed completely under inter-hospital care. In clinical nursing practice, periwound moisture-associated dermatitis should be cared in combination with macerated wounds. We suggest the following: (1) control the moisture source; (2) use advanced dressings as the primary dressing with sterile gauze as a secondary dressing and silver antimicrobial dressings for infected wounds; (3) consider using negative pressure wound therapy for complicated chronic wounds; and (4) use a pH-neutral skin cleanser with non-woven gauze to clean the periwound skin and keep the skin clean and dry. Finally, we suggest isolating and protecting the skin with No Sting Barrier Film and a hydrocolloid dressing. We hope this nursing care experiences serves as a reference for the nursing care of periwound moisture-associated dermatitis resulting from duodenal anastomotic leakage during / after SPK transplantation.
Asunto(s)
Dermatitis/enfermería , Trasplante de Riñón/efectos adversos , Trasplante de Páncreas/efectos adversos , Adulto , Fuga Anastomótica/enfermería , Femenino , Humanos , Terapia de Presión Negativa para HeridasRESUMEN
The mechanism of vascular calcification in CKD is not understood fully, but may involve collagen deposition in the arterial wall upon osteo/chondrocytic transformation of vascular smooth muscle cells (VSMCs). Increased levels of circulating angiopoietin-2 correlate with markers of CKD progression and angiopoietin-2 regulate inflammatory responses, including intercellular and vascular adhesion and recruitment of VSMCs. Here, we investigate the potential role of angiopoietin-2 in the pathogenesis of arterial stiffness associated with CKD. In a cohort of 416 patients with CKD, the plasma level of angiopoietin-2 correlated independently with the severity of arterial stiffness assessed by pulse wave velocity. In mice subjected to 5/6 subtotal nephrectomy or unilateral ureteral obstruction, plasma levels of angiopoietin-2 also increased. Angiopoietin-2 expression markedly increased in tubular epithelial cells of fibrotic kidneys but decreased in other tissues, including aorta and lung, after 5/6 subtotal nephrectomy. Expression of collagen and profibrotic genes in aortic VSMCs increased in mice after 5/6 subtotal nephrectomy and in mice producing human angiopoietin-2. Angiopoietin-2 stimulated endothelial expression of chemokines and adhesion molecules for monocytes, increased Ly6C(low) macrophages in aorta, and increased the expression of the profibrotic cytokine TGF-ß1 in aortic endothelial cells and Ly6C(low) macrophages. Angiopoietin-2 blockade attenuated expression of monocyte chemokines, profibrotic cytokines, and collagen in aorta of mice after 5/6 subtotal nephrectomy. This study identifies angiopoietin-2 as a link between kidney fibrosis and arterial stiffness. Targeting angiopoietin-2 to attenuate inflammation and collagen expression may provide a novel therapy for cardiovascular disease in CKD.
Asunto(s)
Angiopoyetina 1/metabolismo , Angiopoyetina 2/metabolismo , Insuficiencia Renal Crónica/metabolismo , Rigidez Vascular/fisiología , Anciano , Angiopoyetina 1/sangre , Angiopoyetina 2/sangre , Animales , Aorta/inmunología , Aorta/metabolismo , Aorta/patología , Colágeno/metabolismo , Estudios Transversales , Modelos Animales de Enfermedad , Endotelio Vascular/inmunología , Endotelio Vascular/metabolismo , Endotelio Vascular/patología , Femenino , Fibrosis/inmunología , Fibrosis/metabolismo , Fibrosis/patología , Humanos , Inflamación/inmunología , Inflamación/metabolismo , Inflamación/patología , Macrófagos/inmunología , Masculino , Ratones , Ratones Endogámicos C57BL , Persona de Mediana Edad , Receptor TIE-2/sangre , Insuficiencia Renal Crónica/inmunología , Insuficiencia Renal Crónica/patología , Transcriptoma/inmunología , Transcriptoma/fisiología , Factor A de Crecimiento Endotelial Vascular/sangre , Rigidez Vascular/inmunologíaRESUMEN
Fibrosis of the peritoneal cavity remains a serious, life-threatening problem in the treatment of kidney failure with peritoneal dialysis. The mechanism of fibrosis remains unclear partly because the fibrogenic cells have not been identified with certainty. Recent studies have proposed mesothelial cells to be an important source of myofibroblasts through the epithelial-mesenchymal transition; however, confirmatory studies in vivo are lacking. Here, we show by inducible genetic fate mapping that type I collagen-producing submesothelial fibroblasts are specific progenitors of α-smooth muscle actin-positive myofibroblasts that accumulate progressively in models of peritoneal fibrosis induced by sodium hypochlorite, hyperglycemic dialysis solutions, or TGF-ß1. Similar genetic mapping of Wilms' tumor-1-positive mesothelial cells indicated that peritoneal membrane disruption is repaired and replaced by surviving mesothelial cells in peritoneal injury, and not by submesothelial fibroblasts. Although primary cultures of mesothelial cells or submesothelial fibroblasts each expressed α-smooth muscle actin under the influence of TGF-ß1, only submesothelial fibroblasts expressed α-smooth muscle actin after induction of peritoneal fibrosis in mice. Furthermore, pharmacologic inhibition of the PDGF receptor, which is expressed by submesothelial fibroblasts but not mesothelial cells, attenuated the peritoneal fibrosis but not the remesothelialization induced by hypochlorite. Thus, our data identify distinctive fates for injured mesothelial cells and submesothelial fibroblasts during peritoneal injury and fibrosis.
Asunto(s)
Epitelio/patología , Fibroblastos/metabolismo , Peritoneo/patología , Animales , Linaje de la Célula , Colágeno Tipo I/metabolismo , Cadena alfa 1 del Colágeno Tipo I , Células Epiteliales/metabolismo , Fibrosis/patología , Genes Reporteros , Marcadores Genéticos/genética , Proteínas Fluorescentes Verdes/metabolismo , Ácido Hipocloroso/química , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Fibrosis Peritoneal/patología , Tamoxifeno/química , Factor de Crecimiento Transformador beta1/metabolismoRESUMEN
Eugenol-containing restorative materials are commonly used for vital pulp therapy. A well-regulated host defense response is pivotal for the success of vital pulp therapy. The present study was to assess the effects of eugenol on the antimicrobial functions of polymorphonuclear leukocytes (neutrophils). Treatment with eugenol (< or = 1.25 mmol/L) for 30 minutes did not significantly affect the viability of neutrophils. However, preincubation of neutrophils with eugenol (1.25 mmol/L and 2.5 mmol/L) abolished their bactericidal activity against oral pathogens Streptococcus mutans and Actinobacillus actinomycetemcomitans. In addition, through the suppression of the extracellular release of myeloperoxidase and the intracellular production of reactive oxygen species, eugenol at sufficient concentrations impaired the activation of neutrophils by cytochalasin B and fMet-Leu-Phe (CB/fMLP). These results suggested that the antimicrobial functions of neutrophils were interfered by eugenol, and the inhibitory effects of eugenol (< or = 1.25 mmol/L) were not due to direct killing of neutrophils.